Biovail Takes Aim At FDA Over Generic Wellbutrin
Biovail Corp. has filed suit against the U.S. Food and Drug Administration, underscoring that the company does not intend to surrender its lucrative branded drug Wellbutrin XL to generic companies without...To view the full article, register now.
Already a subscriber? Click here to view full article